Kerecis Acknowledged in New Medicare Policy for DFUs
Recently, the Centers for Medicare & Medicaid Services (CMS) finalized a Local Coverage Determination (LCD) policy concerning skin substitute grafts and cellular products used in treating Diabetic Foot Ulcers (DFUs). This important policy adjustment impacts how healthcare services are delivered to patients with this common condition, offering enhanced guidelines for treatment.
Changes in Policy Effectiveness and Scope
The finalized LCD policy introduces notable qualifications aimed at technical proficiency and clinical effectiveness, which differ from earlier proposals. It's important to note that this policy features two distinct lists: one for products related to DFUs and another for those related to venous leg ulcers (VLUs). This structure aims to optimize patient care by allowing for clearer decision-making in clinical settings.
Expanded Treatment Limits
The final policy also extends the application limits for product use, increasing it from 4 to 8 treatments. Additionally, the duration for treatment is boosted from 12 weeks to 16 weeks. These changes indicate a growing recognition of the complexity of treating diabetic foot ailments, reaffirming the need for a comprehensive approach in management and care.
Kerecis Inclusion on Covered Products List
As a remarkable highlight, Kerecis is officially included on the list of covered products for treating DFUs. This recognition underscores the efficacy of Kerecis's products within this important healthcare segment. However, it is worth noting that Kerecis is not yet on the covered products list for VLUs. Presently, sales related to VLUs constitute a small fraction of Kerecis's overall revenue, but the company is proactive in addressing this by conducting clinical studies aimed at expanding their coverage in the future.
Financial Outlook and Growth Projections
While Kerecis has established a strong foundation within the market, the implications of this new policy are significant. The financial projections for Kerecis indicate a robust 3-year compound annual growth rate (CAGR) of around 30% leading into the 2025-2026 fiscal year, with an EBIT margin anticipated to be about 20%. This projection remains steadfast even amidst expected sales losses related to VLUs.
Strategic Adjustments Following Policy Implementation
Following the implementation of the new policy, Kerecis expects some sales loss in the outpatient segment concerning VLUs. Despite this, the overall forecast indicates that growth within the DFUs segment will likely accelerate, offsetting potential losses. This optimistic outlook showcases the resilience and adaptability of Kerecis's market strategies as they navigate the evolving healthcare landscape.
Company Contacts for Stakeholders
For investors seeking further insights, Kerecis’s executive team, including CFO Anders Lonning-Skovgaard, is available for inquiries, ensuring transparent communication regarding company developments. Additionally, Vice President of Investor Relations, Aleksandra Dimovska, can be reached for specific shareholder questions. Their contact information has been included for ease of access, reflecting Kerecis's ongoing commitment to its stakeholders.
Frequently Asked Questions
What is Kerecis's recent announcement regarding DFUs?
Kerecis has been included in the final LCD policy as a covered product for treating Diabetic Foot Ulcers, marking a significant development in healthcare coverage.
How has the final LCD policy changed treatment guidelines?
The policy now allows for an increase in treatment applications and extends the treatment duration from 12 weeks to 16 weeks, enhancing care consistency.
What are the expected financial implications for Kerecis?
Kerecis anticipates a CAGR of approximately 30% until 2026, with an EBIT margin around 20%, even with some expected losses from VLUs.
How does Kerecis plan to address the absence from the VLUs list?
Kerecis is actively conducting clinical studies on VLUs, looking to secure coverage once the studies are complete.
Who can investors contact for information regarding Kerecis?
Investors are encouraged to contact Anders Lonning-Skovgaard, CFO, or Aleksandra Dimovska, VP of Investor Relations, to discuss company updates.
